New lupus drug candidate cenerimod tested in chinese patients

NCT ID NCT07266090

First seen Jan 06, 2026 · Last updated May 15, 2026 · Updated 25 times

Summary

This study is testing an experimental drug called cenerimod in 15 Chinese adults (ages 18-75) with moderate-to-severe systemic lupus erythematosus (SLE) who are already on standard treatments. The goal is to check the drug's safety, how the body handles it, and its effect on immune cells. Participants take one 4 mg tablet daily for up to 12 months and continue their usual lupus medications.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SLE - SYSTEMIC LUPUS ERYTHEMATOSUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, 471003, China

  • First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330200, China

  • Jiujiang NO.1 peple's hospital

    Jiujiang, Jiangxi, 332000, China

  • Peking Union Medical College Hospital

    Beijing, 100010, China

  • The First Affiliated Hospital Of Jinan University

    Guangzhou, Guangdong, 510630, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, 450052, China

  • The Second Hospital of Hebei Medical University

    Shijiazhuang, Hebei, 050000, China

Conditions

Explore the condition pages connected to this study.